Inhibitor development in participants with severe HA (N = 171) and previous CFC exposure
| . | Number of EDs reached . | ||||
|---|---|---|---|---|---|
| ≤10 EDs . | ≤20 EDs . | ≤30 EDs . | ≤40 EDs . | ≤50 EDs . | |
| Participants, n (%) | 47 (27.49) | 61 (35.67) | 71 (41.52) | 72 (42.11) | 171 (100.0) |
| Cumulative inhibitor development, n (%) of 39 total inhibitors | 20 (51.28) | 32 (82.05) | 38 (97.44) | 39 (100.0) | 39 (100.0) |
| . | Number of EDs reached . | ||||
|---|---|---|---|---|---|
| ≤10 EDs . | ≤20 EDs . | ≤30 EDs . | ≤40 EDs . | ≤50 EDs . | |
| Participants, n (%) | 47 (27.49) | 61 (35.67) | 71 (41.52) | 72 (42.11) | 171 (100.0) |
| Cumulative inhibitor development, n (%) of 39 total inhibitors | 20 (51.28) | 32 (82.05) | 38 (97.44) | 39 (100.0) | 39 (100.0) |